Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients

Por de Bruin, Elza C., Whiteley, Jessica L., Corcoran, Claire, Kirk, Pauline M., Fox, Jayne C., Armisen, Javier, Lindemann, Justin P. O., Schiavon, Gaia, Ambrose, Helen J., Kohlmann, Alexander
Publicado no PLoS One (2017)

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

Por Garnett, Sally Anne, Martin, Miguel, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iva, Lichinitser, Mikhail R., Pendergrass, Kelly, Lindemann, Justin P. O., Di Leo, Angelo
Publicado em 2013

AKT Inhibition in Solid Tumors With AKT1 Mutations

Por Hyman, David M., Smyth, Lillian M., Donoghue, Mark T.A., Westin, Shannon N., Bedard, Philippe L., Dean, Emma J., Bando, Hideaki, El-Khoueiry, Anthony B., Pérez-Fidalgo, José A., Mita, Alain, Schellens, Jan H.M., Chang, Matthew T., Reichel, Jonathan B., Bouvier, Nancy, Selcuklu, S. Duygu, Soumerai, Tara E., Torrisi, Jean, Erinjeri, Joseph P., Ambrose, Helen, Barrett, J. Carl, Dougherty, Brian, Foxley, Andrew, Lindemann, Justin P.O., McEwen, Robert, Pass, Martin, Schiavon, Gaia, Berger, Michael F., Chandarlapaty, Sarat, Solit, David B., Banerji, Udai, Baselga, José, Taylor, Barry S.
Publicado no J Clin Oncol (2017)